Myocardial ischemic events in 'Real world' patients with atrial fibrillation treated with dabigatran or warfarin

American Journal of Medicine

Volumn 127, Issue 4, 2014, Pages

  Larsen, Torben Bjerregaard ^a,b   Rasmussen, Lars Hvilsted ^b   Gorst Rasmussen, Anders ^a,b   Skjøth, Flemming ^a,b   Rosenzweig, Mary ^c   Lane, Deirdre A ^b,d   Lip, Gregory Y H ^b,d  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

^c Danish Health and Medicines Authority   (Denmark)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Dabigatran; Effectiveness; Myocardial infarction; Warfarin

Indexed keywords

DABIGATRAN; WARFARIN;

AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; FEMALE; FOLLOW UP; HEART ARREST; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX DIFFERENCE; UNSTABLE ANGINA PECTORIS; VERY ELDERLY;

DABIGATRAN; EFFECTIVENESS; MYOCARDIAL INFARCTION; WARFARIN;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; WARFARIN;

EID: 84897883176     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2013.12.005     Document Type: Article

References (23)

1. A. Banerjee, F. Marín, and G.Y.H. Lip A new landscape for stroke prevention in atrial fibrillation: focus on new anticoagulants, antiarrhythmic drugs, and devices Stroke 42 2011 3316 3322
2. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf et al. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
3. S.J. Connolly, L. Wallentin, and M.D. Ezekowitz et al. The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) study Circulation 128 2013 237 243
4. S.H. Hohnloser, J. Oldgren, and S. Yang et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial Circulation 125 2012 669 676
5. G.Y.H. Lip, and D.A. Lane Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? Am J Med 123 2010 785 789
6. K. Uchino, and A.V. Hernandez Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials Arch Intern Med 172 2012 397 402
7. T.B. Larsen, L.H. Rasmussen, and F. Skjøth et al. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study J Am Coll Cardiol 61 2013 2264 2273
8. W.A. Ray Evaluating medication effects outside of clinical trials: new-user designs Am J Epidemiol 158 2003 915 920
9. R. Sørensen, G. Gislason, and C. Torp-Pedersen et al. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study BMJ Open 3 2013 e002758
10. H.W. Kildemoes, H.T. Sørensen, and J. Hallas The Danish National Prescription Registry Scand J Public Health 39 2011 38 41
11. E. Lynge, J.L. Sandegaard, and M. Rebolj The Danish National Patient Register Scand J Public Health 39 2011 30 33
12. C.B. Pedersen The Danish Civil Registration System Scand J Public Health 39 2011 22 25
13. G. Danaei, L.A.G. Rodríguez, O.F. Cantero, R. Logan, and M.A. Hernán Observational data for comparative effectiveness research: an emulation of randomised trials of statins and primary prevention of coronary heart disease Stat Methods Med Res 22 2013 70 96
14. M.A. Hernán, A. Alonso, and R. Logan et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease Epidemiology 19 2008 766 779
15. S. Toh, and J.E. Manson An analytic framework for aligning observational and randomized trial data: application to postmenopausal hormone therapy and coronary heart disease Stat Biosci 5 2012 344 360
16. D.Y. Lin, L.J. Wei, I. Yang, and Z. Ying Semiparametric regression for the mean and rate functions of recurrent events J R Stat Soc Series B Stat Methodol 62 2000 711 730
17. G.Y.H. Lip, R. Nieuwlaat, R. Pisters, D.A. Lane, and H.J.G.M. Crijns Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation Chest 137 2010 263 272
18. B.F. Gage, C. van Walraven, and L. Pearce et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin Circulation 110 2004 2287 2292
19. R. Pisters, D.A. Lane, R. Nieuwlaat, C.B. de Vos, H.J.G.M. Crijns, and G.Y.H. Lip A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey Chest 138 2010 1093 1100
20. T.A. Gooley, W. Leisenring, J. Crowley, and B.E. Storer Estimation of failure probabilities in the presence of competing risks: new representations of old estimators Stat Med 18 1999 695 706
21. B. Dale, J.W. Eikelboom, and J.I. Weitz et al. Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction? J Thromb Thrombolysis 35 2013 295 301
22. M.D. Ezekowitz, L. Wallentin, and S.J. Connolly et al. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation Circulation 122 2010 2246 2253
23. A.M. Joensen, M.K. Jensen, and K. Overvad et al. Predictive values of acute coronary syndrome discharge diagnoses differed in the Danish National Patient Registry J Clin Epidemiol 62 2009 188 194